E. Ohman J:Or Asset Management Ab Satsuma Pharmaceuticals, Inc. Transaction History

E. Ohman J:Or Asset Management Ab

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2020 Apr 05, 2024	SELL	$3.85 - $28.47 $30,800 - $227,760	-8,000 Closed	0 $0
Q2 2020 Apr 05, 2024	BUY	$16.01 - $34.69 $128,080 - $277,520	8,000 New	8,000 $230 Million

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.